{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:44:49Z","timestamp":1790361889811,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002261","name":"RFBR","doi-asserted-by":"publisher","award":["18-33-01108"],"award-info":[{"award-number":["18-33-01108"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.bmcl.2018.11.018","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T17:48:23Z","timestamp":1541785703000},"page":"40-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework"],"prefix":"10.1016","volume":"29","author":[{"given":"Anton","family":"Shetnev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Osipyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-5816","authenticated-orcid":false,"given":"Sergey","family":"Baykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sapegin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Chirkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Korsakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An\u00e9l","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idalet","family":"Engelbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus P.","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bmcl.2018.11.018_b0005","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2174\/138955707782331722","article-title":"Privileged structures: a useful concept for the rational design of new lead drug candidates","volume":"7","author":"Duarte","year":"2007","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.bmcl.2018.11.018_b0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ejmech.2014.11.028","article-title":"Biologically active compounds based on the privileged 2-imidazoline scaffold: The world beyond adrenergic\/imidazoline receptor modulators","volume":"97","author":"Krasavin","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2018.11.018_b0015","first-page":"561","article-title":"Synthesis of azolines and imidazoles and their use in drug design","volume":"6","author":"Reyes-Arellano","year":"2016","journal-title":"Med Chem (Los Angeles)"},{"issue":"9","key":"10.1016\/j.bmcl.2018.11.018_b0020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(98)01244-9","article-title":"'Seeing through a glass darkly': casting light on imidazoline 'I' sites","volume":"19","author":"Eglen","year":"1998","journal-title":"Trends Pharmacol Sci"},{"issue":"47","key":"10.1016\/j.bmcl.2018.11.018_b0025","doi-asserted-by":"crossref","first-page":"36849","DOI":"10.1074\/jbc.M110.169482","article-title":"Potentiation of ligand binding through cooperative effects in monoamine oxidase B","volume":"285","author":"Bonivento","year":"2010","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2018.11.018_b0030","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/ci400346k","article-title":"Computational comparison of imidazoline association with the I2 binding site in human monoamine oxidases","volume":"54","author":"Basile","year":"2014","journal-title":"J Chem Inf Model"},{"issue":"4","key":"10.1016\/j.bmcl.2018.11.018_b0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat Rev Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.bmcl.2018.11.018_b0040","first-page":"25","article-title":"A neuroscientific update on monoamine oxidase and its inhibitors","volume":"18","author":"Schwartz","year":"2013","journal-title":"CNS Spectr"},{"issue":"3","key":"10.1016\/j.bmcl.2018.11.018_b0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1092852912000594","article-title":"Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression","volume":"17","author":"Lum","year":"2012","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.bmcl.2018.11.018_b0050","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3892\/mmr.2014.2040","article-title":"Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review)","volume":"9","author":"Cai","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.bmcl.2018.11.018_b0055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coph.2017.04.003","article-title":"Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease","volume":"33","author":"Deshwal","year":"2017","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"10.1016\/j.bmcl.2018.11.018_b0060","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1172\/JCI70982","article-title":"Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis","volume":"124","author":"Wu","year":"2014","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.bmcl.2018.11.018_b0065","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.bmcl.2008.03.001","article-title":"Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors","volume":"19","author":"Sant' Anna Gda","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.bmcl.2018.11.018_b0070","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0022-3565(25)24461-5","article-title":"Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites","volume":"272","author":"Carpene","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.bmcl.2018.11.018_b0075","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/sj.bjp.0701214","article-title":"Inhibition of monoamine oxidase A and B activities by imidazol(ine)\/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver","volume":"121","author":"Ozaita","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2018.11.018_b0080","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejmech.2015.12.026","article-title":"Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold","volume":"108","author":"Distinto","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"41","key":"10.1016\/j.bmcl.2018.11.018_b0085","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.1016\/j.tetlet.2015.08.062","article-title":"Atom-economical construction of tetracyclic [1,4]oxazepines involving intramolecular arylation of a 2-imidazoline moiety","volume":"56","author":"Karamysheva","year":"2015","journal-title":"Tetrahedron Lett"},{"issue":"21","key":"10.1016\/j.bmcl.2018.11.018_b0090","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1016\/j.tetlet.2015.04.059","article-title":"Facile Pd-catalyzed amination of imidazolin-1-yl chloroazines under microwave irradiation: toward a new kinase-inhibitory chemotype","volume":"56","author":"Mujumdar","year":"2015","journal-title":"Tetrahedron Lett."},{"issue":"3","key":"10.1016\/j.bmcl.2018.11.018_b0095","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.tet.2006.11.007","article-title":"One-pot synthesis of imidazolines from aldehydes: detailed study about solvents and substrates","volume":"63","author":"Fujioka","year":"2007","journal-title":"Tetrahedron"},{"issue":"7","key":"10.1016\/j.bmcl.2018.11.018_b0100","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.tet.2017.01.007","article-title":"The first one-pot ambient-temperature synthesis of 1,2,4-oxadiazoles from amidoximes and carboxylic acid esters","volume":"73","author":"Baykov","year":"2017","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmcl.2018.11.018_b0105","unstructured":"Zhu B-Y, Bauer SM, Jia ZJ, Probst GD, Zhang Y, Scarborough RM. Factor Xa inhibitors. WO 2006002099 A2."},{"key":"10.1016\/j.bmcl.2018.11.018_b0110","unstructured":"Roberts E, Rosen H, Brown S, Morales M, Peng X, Poddutoori R. Novel modulators of sphingosine phosphate receptors. WO 2009151529 A1."},{"issue":"5","key":"10.1016\/j.bmcl.2018.11.018_b0115","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cmdc.201500059","article-title":"Indanones as high-potency reversible inhibitors of monoamine oxidase","volume":"10","author":"Mostert","year":"2015","journal-title":"ChemMedChem"},{"issue":"22","key":"10.1016\/j.bmcl.2018.11.018_b0120","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1016\/j.bmc.2005.06.043","article-title":"Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening","volume":"13","author":"Novaroli","year":"2005","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2018.11.018_b0125","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1055\/s-0033-1345163","article-title":"The inhibition of monoamine oxidase by esomeprazole","volume":"63","author":"Petzer","year":"2013","journal-title":"Drug Res (Stuttg)"},{"issue":"16","key":"10.1016\/j.bmcl.2018.11.018_b0130","doi-asserted-by":"crossref","first-page":"15761","DOI":"10.1074\/jbc.M500949200","article-title":"Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors","volume":"280","author":"Hubalek","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2018.11.018_b0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nsb732","article-title":"Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders","volume":"9","author":"Binda","year":"2002","journal-title":"Nat Struct Biol"},{"issue":"15","key":"10.1016\/j.bmcl.2018.11.018_b0140","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1073\/pnas.0710626105","article-title":"Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates\/inhibitors","volume":"105","author":"Son","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"10.1016\/j.bmcl.2018.11.018_b0145","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18308837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18308837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:25:58Z","timestamp":1760772358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X18308837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0960894X18308837"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.11.018","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}